Severe coronavirus disease 2019 (COVID‐19) pneumonia patients treated successfully with a combination of lopinavir/ritonavir plus favipiravir: Case series. Issue 12 (25th September 2020)

• Record Type: Journal Article
• Authors: Koba, Hayato; Yoneda, Taro; Kaneda, Tomoya; Ueda, Tsukasa; Kimura, Hideharu; Kasahara, Kazuo
• Is Part Of: Clinical case reports. Volume 8:Issue 12(2020)
• Page Start: 3142
• Page End: 3147
• Publication Date: 2020-09-25
• Subjects: COVID‐19 -- favipiravir -- ferritin -- Lopinavir -- lymphocytopenia -- ritonavir; Medicine -- Periodicals; 616.09
• DOI: 10.1002/ccr3.3358
• Languages: English
• ISSNs: 2050-0904

Abstract

Key Clinical Message: The combination therapy of Lopinavir/Ritonavir plus Favipiravir might be a treatment option for patients with COVID‐19. Serum ferritin levels and lymphocytopenia are promising markers for disease severity and disease progression that are commonly available in general clinical practice. Abstract : This is the first report to present a promising anti‐viral combination therapy, Lopinavir/Ritonavir plus Favipiravir, for COVID‐19 patients. Serum ferritin levels and lymphocytopenia might be markers for disease severity and disease progression.